Vermillion
The company is developing tests for ovarian mass monitoring and endometriosis that it hopes will expand its addressable market beyond that targeted by OVA1.
Aspira Women's Health Q1 Revenues Up 25 Percent
The company's Q1 revenues rose to $1.5 million from $1.2 million as it performed 3,775 OVA1 tests, up 3 percent from 3,654 tests in Q1 2020.
Aspira Prices $45M Offering of Common Stock
The company, formerly called Vermillion, plans to offer 6 million shares of its common stock at $7.50 per share.
In Brief This Week: BioReference Laboratories, PerkinElmer, Fluidigm, Invitae, and More
News items for the in vitro diagnostics industry for the week of Jan. 25, 2021.
Aspira Collaborating With Baylor Genetics on Ovarian Cancer Early Detection Test
Aspira said it will bring its experience in patient sample recruitment and ovarian cancer assay development to the collaboration.